---
layout: default
title: Nitrous Oxide
parent: Model Prediction Only (L5)
nav_order: 558
evidence_level: L5
indication_count: 1
---

# Nitrous Oxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nitrous Oxide: From Inhalational Anesthesia/Analgesia to Benign Prostatic Hyperplasia

## One-Sentence Summary

Nitrous oxide is a well-known inhalational anesthetic/analgesic agent, most commonly used for procedural sedation and pain relief (e.g., during minor surgical or diagnostic procedures). The TxGNN model predicts a possible association with **Benign Prostatic Hyperplasia**, but the supporting evidence is currently limited to **1 clinical trial** (procedural analgesia during prostate biopsy, not BPH treatment itself) and **3 older publications**, none of which directly test nitrous oxide as a BPH therapy.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available from regulatory data; based on general pharmacological knowledge, nitrous oxide is used as an inhalational anesthetic/analgesic for procedural sedation |
| Predicted New Indication | Benign Prostatic Hyperplasia |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L4 (indirect clinical/procedural evidence, no direct efficacy studies for BPH treatment) |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for nitrous oxide (Data Gap). Based on known pharmacology, nitrous oxide is an inhaled agent with anesthetic, analgesic, and anxiolytic properties, commonly used for procedural sedation in dental, obstetric, and minor surgical settings.

The single clinical trial identified (NCT05803096) used self-administered nitrous oxide to reduce anxiety and pain **during transrectal prostate biopsy** — a diagnostic procedure for prostate cancer, not a treatment for benign prostatic hyperplasia itself. This suggests the TxGNN association may reflect a statistical/procedural co-occurrence (nitrous oxide being used in patients undergoing prostate-related procedures) rather than a genuine pharmacological effect on BPH pathophysiology.

The identified literature is similarly indirect: it consists of older case reports and technical notes involving anesthesia during prostate surgery, rather than studies evaluating nitrous oxide's therapeutic effect on prostatic tissue or lower urinary tract symptoms. Given the absence of MOA data and the lack of any study directly testing efficacy for BPH, the mechanistic plausibility of this prediction remains unconfirmed.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT05803096](https://clinicaltrials.gov/study/NCT05803096) | Phase 4 | Completed | 143 | Evaluated self-administered nitrous oxide during transrectal prostate biopsy to reduce patient anxiety and pain; addresses procedural tolerability, not BPH treatment efficacy |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9223887](https://pubmed.ncbi.nlm.nih.gov/9223887/) | 1997 | Case report (unclassified) | Masui (Jpn J Anesthesiology) | Case report of general anesthesia (including nitrous oxide) for suprapubic prostatectomy in a patient with pure autonomic failure; focuses on anesthetic management, not BPH treatment |
| [4108916](https://pubmed.ncbi.nlm.nih.gov/4108916/) | 1971 | Unclassified (no abstract available) | Zeitschrift für praktische Anästhesie und Wiederbelebung | Title indicates combination anesthesia (methohexital) in high-risk urologic patients; no abstract available to assess relevance to BPH |
| [4171323](https://pubmed.ncbi.nlm.nih.gov/4171323/) | 1968 | Unclassified (no abstract available) | International Surgery | Title describes a new apparatus for cryotherapy of prostate obstruction; no abstract available, direct relevance to nitrous oxide/BPH unclear |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction score is high, but the supporting clinical and literature evidence is indirect — it documents nitrous oxide's use as a procedural adjunct during prostate-related interventions rather than its efficacy in treating BPH. Combined with a blocking data gap in TFDA/product monograph warnings and contraindications, and the absence of MOA data, the evidence base is currently insufficient to support progression.

**To proceed, the following is needed:**
- TFDA/Health Canada product monograph warnings, contraindications, and precautions (currently blocking safety review)
- Mechanism of action data from DrugBank
- Direct clinical or preclinical evidence evaluating nitrous oxide's effect on prostatic tissue, lower urinary tract symptoms, or BPH progression (not just procedural analgesia)
- Clarification of whether the TxGNN association reflects a genuine pharmacological signal or confounding from co-occurrence in urological procedure settings
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

